Published in Int J Cancer on March 31, 1999
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res (2009) 2.17
Immunotoxins for targeted cancer therapy. AAPS J (2006) 1.86
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res (2009) 1.84
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A (2008) 1.66
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res (2011) 1.54
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A (2012) 1.42
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 1.25
Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci U S A (2000) 1.20
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.06
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs (2009) 1.05
Production of unique immunotoxin cancer therapeutics in algal chloroplasts. Proc Natl Acad Sci U S A (2012) 1.01
A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. Protein Eng Des Sel (2011) 0.93
An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. Leuk Res (2014) 0.88
Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem (2010) 0.83
Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget (2013) 0.82
Immunoconjugates in the management of hairy cell leukemia. Best Pract Res Clin Haematol (2015) 0.82
Preparation and characterization of a novel chimeric protein VEGI-CTT in Escherichia coli. J Biomed Biotechnol (2008) 0.75
Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther (2017) 0.75
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A (1982) 20.55
Cyclic AMP receptor protein of E. coli: its role in the synthesis of inducible enzymes. Proc Natl Acad Sci U S A (1970) 13.26
Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem (1993) 10.95
Pleiotropic deficiency of carbohydrate utilization in an adenyl cyclase deficient mutant of Escherichia coli. Biochem Biophys Res Commun (1969) 9.20
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 8.53
Cyclic adenosine 5'-monophosphate in Escherichia coli. Bacteriol Rev (1976) 7.55
Regulation of beta-galactosidase synthesis in Escherichia coli by cyclic adenosine 3',5'-monophosphate. J Biol Chem (1968) 7.54
Cyclic adenosine monophosphate in bacteria. Science (1970) 7.53
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A (1987) 7.38
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol (1999) 6.62
Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells. Proc Natl Acad Sci U S A (1978) 6.59
Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65
Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus. Cell (1980) 5.51
Restoration of several morphological characteristics of normal fibroblasts in sarcoma cells treated with adenosine-3':5'-cyclic monphosphate and its derivatives. Proc Natl Acad Sci U S A (1971) 5.31
Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem (1980) 5.24
Structure of the promoter for chicken alpha 2 type I collagen gene. Proc Natl Acad Sci U S A (1981) 4.89
In vitro transcription of the gal operon requires cyclic adenosine monophosphate and cyclic adenosine monophosphate receptor protein. J Biol Chem (1971) 4.58
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A (1987) 4.43
Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1980) 4.35
Cell surface protein partially restores morphology, adhesiveness, and contact inhibition of movement to transformed fibroblasts. Proc Natl Acad Sci U S A (1976) 4.32
Localization of the ASV src gene product to the plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1979) 4.30
Cyclic 3'5-AMP: stimulation of beta-galactosidase and tryptophanase induction in E. coli. Biochem Biophys Res Commun (1968) 4.16
Identification of two lysosomal membrane glycoproteins. J Cell Biol (1985) 4.08
Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci U S A (1985) 4.08
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
Collection of insulin, EGF and alpha2-macroglobulin in the same patches on the surface of cultured fibroblasts and common internalization. Cell (1978) 3.90
The receptosome: an intermediate organelle of receptor mediated endocytosis in cultured fibroblasts. Cell (1980) 3.88
Regulation of inducible enzyme synthesis in Escherichia coli by cyclic adenosine 3', 5'-monophosphate. J Biol Chem (1969) 3.86
Levels of translatable mRNAs for cell surface protein, collagen precursors, and two membrane proteins are altered in Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A (1977) 3.80
Lac DNA, RNA polymerase and cyclic AMP receptor protein, cyclic AMP, lac repressor and inducer are the essential elements for controlled lac transcription. Nat New Biol (1971) 3.79
The collagen gene: evidence for its evolutinary assembly by amplification of a DNA segment containing an exon of 54 bp. Cell (1980) 3.66
Promoter region of the human Harvey ras proto-oncogene: similarity to the EGF receptor proto-oncogene promoter. Science (1985) 3.59
Cyclic AMP levels in fibroblasts: relationship to growth rate and contact inhibition of growth. Biochem Biophys Res Commun (1971) 3.58
Cyclic AMP regulates catabolite and transient repression in E. coli. Nature (1969) 3.42
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science (1992) 3.41
Glucose depletion accounts for the induction of two transformation-sensitive membrane proteinsin Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A (1977) 3.26
Regulation of lac mRNA synthesis in a soluble cell-free system. Nat New Biol (1971) 3.25
Isolation and characterization of myosin from cloned mouse fibroblasts. Proc Natl Acad Sci U S A (1972) 3.24
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet (1985) 3.23
Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science (1986) 3.22
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A (1986) 3.19
A key role of starburst amacrine cells in originating retinal directional selectivity and optokinetic eye movement. Neuron (2001) 3.18
Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res (1985) 3.15
The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem (1987) 3.13
Effect of adenosine 3',5'-monophosphate analogues on the activity of the cyclic adenosine 3',5'-monophosphate receptor in Escherichia coli. J Biol Chem (1972) 3.08
The major cell surface glycoprotein of chick embryo fibroblasts is an agglutinin. Proc Natl Acad Sci U S A (1975) 3.06
Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science (1984) 3.06
Microfilament bundles and cell shape are related to adhesiveness to substratum and are dissociable from growth control in cultured fibroblasts. Cell (1977) 2.99
Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem (1986) 2.93
Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell (1987) 2.93
The role of the lac promotor locus in the regulation of beta-galactosidase synthesis by cyclic 3',5'-adenosine monophosphate. Proc Natl Acad Sci U S A (1968) 2.92
The visualization of fluorescent proteins in living cells by video intensification microscopy (VIM). Cell (1978) 2.89
HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87
Regulation of cell growth by cyclic adenosine 3',5'-monophosphate. Effect of cell density and agents which alter cell growth on cyclic adenosine 3',5'-monophosphate levels in fibroblasts. J Biol Chem (1972) 2.85
Multiple-drug resistance in human cancer. N Engl J Med (1987) 2.76
Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell (1983) 2.74
Effect of Rho on transcription of bacterial operons. Nat New Biol (1973) 2.74
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
The multidrug transporter, a double-edged sword. J Biol Chem (1988) 2.61
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature (1988) 2.55
Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem (1993) 2.52
Induction of two transformation-sensitive membrane polypeptides in normal fibroblasts by a block in glycoprotein synthesis or glucose deprivation. Cell (1977) 2.52
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer (1992) 2.50
Unusual features in the nucleotide sequence of a cDNA clone derived from the common region of avian sarcoma virus messenger RNA. Proc Natl Acad Sci U S A (1980) 2.45
ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci U S A (1988) 2.44
alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A (1997) 2.43
Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A (1984) 2.42
Amines inhibit the clustering of alpha2-macroglobulin and EGF on the fibroblast cell surface. Nature (1979) 2.41
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40
Clostridium barkeri sp. n. J Bacteriol (1972) 2.38
Unusual methylation pattern of the alpha 2 (l) collagen gene. Cell (1982) 2.36
Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature (1984) 2.36
P-glycoprotein and multidrug resistance. Curr Opin Genet Dev (1996) 2.33
Small RNA regulators and the bacterial response to stress. Cold Spring Harb Symp Quant Biol (2006) 2.31
Genetic analysis of the multidrug transporter. Annu Rev Genet (1995) 2.29
Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet (1986) 2.27
Quantitative determination of the lateral diffusion coefficients of the hormone-receptor complexes of insulin and epidermal growth factor on the plasma membrane of cultured fibroblasts. Proc Natl Acad Sci U S A (1978) 2.26
Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol (2000) 2.24
alpha 2-macroglobulin adsorbed to colloidal gold: a new probe in the study of receptor-mediated endocytosis. J Cell Biol (1981) 2.19
Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A (1984) 2.18
Isolation and characterization of overlapping genomic clones covering the chicken alpha 2 (type I) collagen gene. Proc Natl Acad Sci U S A (1980) 2.18
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res (1986) 2.12
Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci U S A (1990) 2.12
Down-regulation of the epidermal growth factor receptor in KB cells is due to receptor internalization and subsequent degradation in lysosomes. Proc Natl Acad Sci U S A (1984) 2.11
Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell (1983) 2.11
Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci U S A (1997) 2.10
ACTH receptors in the adrenal: specific binding of ACTH-125I and its relation to adenyl cyclase. Proc Natl Acad Sci U S A (1970) 2.09
Binding of the Sp1 transcription factor by the human Harvey ras1 proto-oncogene promoter. Science (1986) 2.08
Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci U S A (1986) 2.08
Use of recombinant plasmids to characterize collagen RNAs in normal and transformed chick embryo fibroblasts. J Biol Chem (1979) 2.07
Recombinant toxins as novel therapeutic agents. Annu Rev Biochem (1992) 2.05
Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem (1990) 2.04
Regulation of cell motility by cyclic AMP. Nature (1972) 2.03